The departure of Gregory Geba from the helm of FDA’s generic drugs office should not create immediate problems, but could become a significant issue if not filled in a timely fashion.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?